Evidence map›Paper›PMID 31966548›Full record

ArticleInternational journal of clinical and experimental pathology2017

Inhibition of SERPINE2/protease nexin-1 by a monoclonal antibody attenuates airway remodeling in a murine model of asthma.

Chengping Hu, Juan Jiang, Qiufen Xun, Bingrong Zhao, Xinyue Hu, Pengbo Deng, Yuanyuan Li

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chengping HuDepartment of Respiratory Medicine (Department of Respiratory and Critical Care Medicine), Key Cite of National Clinical Research Center for Respiratory Diseases, Xiangya Hospital, Central South University Changsha 410008, China.
Juan JiangDepartment of Respiratory Medicine (Department of Respiratory and Critical Care Medicine), Key Cite of National Clinical Research Center for Respiratory Diseases, Xiangya Hospital, Central South University Changsha 410008, China.
Qiufen XunDepartment of Respiratory Medicine (Department of Respiratory and Critical Care Medicine), Key Cite of National Clinical Research Center for Respiratory Diseases, Xiangya Hospital, Central South University Changsha 410008, China.
Bingrong ZhaoDepartment of Respiratory Medicine (Department of Respiratory and Critical Care Medicine), Key Cite of National Clinical Research Center for Respiratory Diseases, Xiangya Hospital, Central South University Changsha 410008, China.
Xinyue HuDepartment of Respiratory Medicine (Department of Respiratory and Critical Care Medicine), Key Cite of National Clinical Research Center for Respiratory Diseases, Xiangya Hospital, Central South University Changsha 410008, China.
Pengbo DengDepartment of Respiratory Medicine (Department of Respiratory and Critical Care Medicine), Key Cite of National Clinical Research Center for Respiratory Diseases, Xiangya Hospital, Central South University Changsha 410008, China.
Yuanyuan LiDepartment of Respiratory Medicine (Department of Respiratory and Critical Care Medicine), Key Cite of National Clinical Research Center for Respiratory Diseases, Xiangya Hospital, Central South University Changsha 410008, China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SERPINE2, also known as protease nexin-1 (PN-1), is a serine protease inhibitor produced by many cell types and has pleiotropic biological functions. It has been reported that SERPINE2/PN-1 is involved in tissue remodeling of fibrotic diseases including idiopathic pulmonary fibrosis and cardiac fibrosis. However, the potential role of SERPINE2/PN-1 in asthmatic airway remodeling has remained barely investigated so far. In this study, BALB/c male mice were sensitized and challenged by ovalbumin to generate murine models of airway remodeling. Anti-SERPINE2 monoclonal antibody was intraperitoneally injected into these mice during the ovalbumin challenge while IgG antibody was used as a vehicle control. The results revealed that the expression of SERPINE2/PN-1 was significantly upregulated in the lung extracts of ovalbumin-challenged mice, and this upregulation was inhibited by dexamethasone. Sustained ovalbumin stimulation increased the thickness of airway wall and α-SMA positive areas in lung, which was attenuated by the treatment with SERPINE2 antibody. In addition, SERPINE2 antibody partially blocked the phosphorylation of ERK, and reduced the upregulation of MMP-9 and TIMP-1 expressions in asthmatic mice. These findings suggest that SERPINE2/PN-1 may play a role in the pathologic development of airway remodeling. Monoclonal antibody against SERPINE2 may have the potential as an effective pharmacotherapy for asthmatic airway remodeling.

Indexed as

airway remodelingAsthmamonoclonal antibodyprotease nexin-1SERPINE2

Identifiers

PMID31966548
PMCPMC6966070
OpenAlexW3018854229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.